Deutsche Bank Reaffirms Hold Rating for GlaxoSmithKline (GSK)

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by investment analysts at Deutsche Bank in a research note issued to investors on Thursday. They currently have a GBX 1,440 ($20.19) price objective on the stock. Deutsche Bank’s price objective points to a potential upside of 11.54% from the stock’s previous close.

A number of other research analysts have also issued reports on the stock. Societe Generale restated a “sell” rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Berenberg Bank decreased their target price on shares of GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a “buy” rating on the stock in a research report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($20.33) target price on shares of GlaxoSmithKline and gave the stock a “sell” rating in a research report on Monday, November 6th. Barclays restated an “equal weight” rating and set a GBX 1,450 ($20.33) target price on shares of GlaxoSmithKline in a research report on Friday, October 27th. Finally, JPMorgan Chase & Co. decreased their target price on shares of GlaxoSmithKline from GBX 1,570 ($22.01) to GBX 1,330 ($18.65) and set a “neutral” rating on the stock in a research report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and a consensus price target of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during trading hours on Thursday, hitting GBX 1,291 ($18.10). 11,680,000 shares of the company’s stock were exchanged, compared to its average volume of 9,480,000. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18). The firm has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52.

In other GlaxoSmithKline news, insider Sir Roy Anderson purchased 562 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was purchased at an average price of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Insiders acquired 581 shares of company stock worth $743,284 in the last 90 days.

WARNING: “Deutsche Bank Reaffirms Hold Rating for GlaxoSmithKline (GSK)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/11/deutsche-bank-reaffirms-hold-rating-for-glaxosmithkline-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply